Prestige Consumer Healthcare Inc. (PBH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 963 | 943 | 1,087 | 1,128 | 1,125 | 1,138 | 1,089 | 1,105 |
| Operating profit | $m | 309 | 290 | ||||||
| Net profit | $m | 142 | 165 | 205 | -82 | 209 | 215 | 190 | 172 |
| EPS reported | $ | 3.91 | 3.57 | ||||||
| Operating cashflow per share | $ | 5.32 | 5.25 | ||||||
| Capex per share | $ | 0.23 | 0.30 | ||||||
| FCF per share | $ | 5.09 | 4.96 | ||||||
| Free cash flow | $m | 246 | 235 | ||||||
| Net debt | $m | 933 | 1,929 | ||||||
| Book value equity | $m | 1,888 | 1,917 | ||||||
| Book value per share | $ | 38.74 | 40.26 | ||||||
| Number of shares | m | 48.72 | 47.6 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 10.17 | 13.06 | ||||||
| P/B LTM | x | 1.52 | 2.23 | ||||||
| P/S LTM | x | 1.70 | 3.87 | ||||||
| P/FCF LTM | x | 11.65 | 18.15 | ||||||
| EV/EBITDA LTM | x | 10.55 | 16.69 | ||||||
| EV/Sales LTM | x | 2.97 | 3.99 | ||||||
| Earnings Yield LTM | % | +8.78% | +7.66% | ||||||
| FCF Yield | % | +8.58% | +5.51% | ||||||
| Quality | |||||||||
| ROE | % | +10.08% | +9.22% | ||||||
| ROIC | % | +6.65% | +4.80% | ||||||
| Operating margin | % | +28.42% | +26.26% | ||||||
| Gross margin | % | +52.78% | +53.26% | ||||||
| FCF/Sales | % | +22.64% | +21.30% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -8.86% | -14.39% | ||||||
| Sales Growth YoY | % | -4.31% | -1.82% | ||||||
| Net Income Growth YoY | % | -11.32% | -17.83% | ||||||
| FCF Growth | % | +1.30% | -1.68% | ||||||
| Operating Profit Growth | % | -8.13% | -15.26% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.24 | 0.11 | ||||||
| Net Debt/EBITDA | x | 2.96 | 6.31 | ||||||
| EBIT/Net interest | x | 7.31 | 6.30 | ||||||
| Net debt/market cap | % | +34.71% | +82.90% | ||||||
| Net debt/Equity | x | 0.49 | 1.01 | ||||||
| Gross debt/equity | x | 0.55 | 1.08 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Prestige Consumer Healthcare Inc. (PBH)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free